Beginning Cash: The amount of cash reported by the company on its previous statement.
Kymera Therapeutics, Inc. (KYMR) had Beginning Cash of $362.81M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$34.37M |
|
$-69.23M |
|
-- |
|
$34.37M |
|
$118.52M |
|
$-84.15M |
|
$14.92M |
|
$-69.23M |
|
$-69.23M |
|
$-69.23M |
|
$-69.23M |
|
$-69.23M |
|
$-69.23M |
|
$-84.15M |
|
$-84.86M |
|
97.53M |
|
97.53M |
|
$-0.71 |
|
$-0.71 |
|
| Balance Sheet Financials | |
$677.43M |
|
$41.62M |
|
$991.58M |
|
$1.67B |
|
$62.64M |
|
$1.15M |
|
$66.74M |
|
$129.38M |
|
$1.54B |
|
$1.54B |
|
$1.54B |
|
82.18M |
|
| Cash Flow Statement Financials | |
$-88.84M |
|
$-142.84M |
|
$18.77M |
|
|
Beginning Cash |
$362.81M |
$149.90M |
|
$-212.91M |
|
$16.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.81 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
100.00% |
|
-244.88% |
|
-244.88% |
|
-- |
|
-201.47% |
|
-201.47% |
|
$-89.27M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-4.50% |
|
-4.50% |
|
-4.15% |
|
-4.49% |
|
$18.73 |
|
$-0.92 |
|
$-0.91 |
|